“Currently there are only experimental Ebola treatments in the earliest stages of development. Even though a drug is not approved right now, the U.S. Food and Drug Administration can still provide access to potential products through other mechanisms, such as through an emergency Investigational New Drug (IND) application. The FDA stands ready to work with companies and investigators treating these patients who are in dire need of treatment.  Regarding Ebola, the FDA is involved in an inter-agency working group led by Assistant Secretary for Preparedness and Response (ASPR)/Biomedical Advanced Research and Development Authority (BARDA). This working group is looking to facilitate and accelerate development of potential investigation treatments for Ebola. The FDA’s role involves sharing information about medical products in development as well as communicating our assessment of product readiness and clarifying regulatory pathways for development. More